METASTATIC BLADDER PARAGANGLIOMA WITH UNDERLYING SHDB MUTATION

Authors

  • Ooi Xin Yi Hospital Kuala Lumpur, Malaysia

Keywords:

paraganglioma

Abstract

INTRODUCTION
Phaeochromocytoma and paraganglioma (PPGL) are rare tumors with up to 40% associated with inherited germline mutations. SHDB mutation is associated with an increased risk of metastasis.

CASE
A 36-year-old male presented with hypertensive emergency. He was diagnosed to have a bladder paraganglioma at age 32 when he presented with hypertensive crisis. Ga-68 DOTANOC PET/CT scan then showed a localized 4.7 x 5.3 cm bladder paraganglioma and he underwent complete surgical resection with resolution of his symptoms. Genetic testing done showed SHDB, deletion (exon 1), heterogenous pathogenic variant. He remained asymptomatic and was lost to follow-up due to Covid-19 until his recent admission.

During this admission, he had labile blood pressure with symptoms of palpitations and lethargy. He was found to have a 4.3 x elevated urine normetanephrine (1639 ug/day, N<374.7). Metanephrine and 3-methoxytyramine levels were normal. His blood pressure was controlled with phenoxybenzamine 20 mg TDS (1 mg/kg), telmisartan 40 mg OM and carvedilol 25 mg BD with improvement in his symptoms. Subsequent anatomical imaging with CT and functional imaging with Ga-68 DOTATATE showed a small recurrence at the bladder wall with metastatic lesions at the left sacral ala measuring 4.5 x 5.1 cm, and multiple lytic lesions over the spine, ribs and also the left acetabulum with the highest uptake of Ga-68 DOTATATE at the C2 vertebra (SUV max 93). He is now planned for peptide receptor radionuclide therapy (PRRT).

SHDB mutation is associated with a higher risk of metastatic disease which has remained unexplained. Treatment for metastatic disease include surgical resection where possible, targeted therapy such as PRRT, meta-iodobenzylguanidine (MIBG) therapy, radiotherapy and also systemic therapy such as chemotherapy and tyrosine kinase inhibitors.

CONCLUSION
Patients with PPGL, especially those with SHDB mutation, require monitoring at regular intervals to screen and detect metastasis to reduce mortality and morbidity.

Downloads

Download data is not yet available.

References

*

Downloads

Published

2022-07-15

How to Cite

Yi, O. X. . (2022). METASTATIC BLADDER PARAGANGLIOMA WITH UNDERLYING SHDB MUTATION. Journal of the ASEAN Federation of Endocrine Societies, 37, 50–51. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/2323